FTLD

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Retrieved on: 
Monday, April 1, 2024
Research, PMN, FTLD, Biotechnology, MSA, ALS, Multiple system atrophy, CSF, Patient, Neuroscience, Epitope, Immunoglobulin G, RACK1, Cerebrospinal fluid, Activated, Synucleinopathy, Clinical trial, PROMIS, Antibody, Vaccination, Safety, Pharmacokinetics, Interim, Therapy, Blood, SAD, Frontotemporal lobar degeneration, Pharmaceutical industry

This is a very exciting opportunity for both ProMIS and the AD patients we aim to serve.

Key Points: 
  • This is a very exciting opportunity for both ProMIS and the AD patients we aim to serve.
  • ProMIS dosed the first participants in a first-in-human Phase 1a clinical trial of PMN310 as a potential treatment for AD in November 2023 (Study NCT06105528 ).
  • Using a proprietary computational platform, ProMIS identified potential conformational epitopes (misfolded portions) unique to toxic alpha-synuclein involved in synucleinopathies.
  • Cash and cash equivalents were $12.6 million as of December 31, 2023, compared to $5.9 million as of December 31, 2022.

ProMIS Neurosciences Issues Letter to Shareholders

Retrieved on: 
Monday, January 8, 2024
PROMIS, Intellectual property, ALS, MSA, Multiple system atrophy, Antibody, Letter, Frontotemporal lobar degeneration, Trial of the century, Brain, MD, RACK1, Epitope, PMN, Artificial intelligence, SAD, FTLD, Growth, Safety, Patient, Dementia, Therapy, Pharmaceutical industry

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Issues Letter to ShareholderProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that its Chief Executive Officer, Neil Warma, issued the following letter to the Company’s shareholders.

Key Points: 
  • TORONTO, Ontario and CAMBRIDGE, Massachusetts, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Issues Letter to ShareholderProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that its Chief Executive Officer, Neil Warma, issued the following letter to the Company’s shareholders.
  • Our ultimate goal is to get these potential new drugs to patients who are in desperate need of safe and effective treatment options.
  • This specificity is expected to improve efficacy outcomes and prevent any off-target safety issues, which are common with other AD therapies currently marketed or in development.
  • As we navigate this transformative period, I am confident that ProMIS will emerge stronger, more resilient, and better positioned to make significant contributions to healthcare.

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Retrieved on: 
Wednesday, December 20, 2023
PROMIS, ALS, MSA, Neuroscience, Multiple system atrophy, Cytoplasm, FUS, Frontotemporal lobar degeneration, Disease, RACK1, PMN, TAR, Activated, FTLD, Cell, Therapy, Neuron

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced a publication identifying Receptor for Activated C-Kinase 1 (RACK1) as a novel misfolded protein target for ALS and frontotemporal lobar degeneration (FTLD). The article published in the online edition of Acta Neuropathologica Communications is titled, "Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration."

Key Points: 
  • The article published in the online edition of Acta Neuropathologica Communications is titled, "Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration."
  • Under normal conditions, TDP-43 and FUS are predominantly localized in the nucleus of cells, where they participate in the regulation of protein expression.
  • In disease, however, they typically become mislocalized in the cytoplasm of neurons where they form aggregates.
  • The study authors reported that pathological FUS and TDP-43 both co-aggregate with RACK1 resulting in suppression of protein synthesis.

ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting

Retrieved on: 
Monday, April 24, 2023
Neuron, FTLD, PMN, Plaque, Therapy, Date-time group, PROMIS, Frontotemporal lobar degeneration, AAN, Pathology, Multiple system atrophy, American Academy, Brain, RACK1, Antibody, Dementia, TAR, ARIA, Patient, MSA, Risk, Neuroscience, TSX, Poster, Cerebral edema, AD, ALS, Pharmaceutical industry, Vaccine, Flour, Drosophila melanogaster

The data were presented in poster presentations on April 23 at the 75th American Academy of Neurology (AAN) Annual Meeting in Boston, MA.

Key Points: 
  • The data were presented in poster presentations on April 23 at the 75th American Academy of Neurology (AAN) Annual Meeting in Boston, MA.
  • “We are pleased to share progress highlighting our ongoing effort to develop next-generation therapies for debilitating neurodegenerative disorders,” said Gail Farfel, Ph.D., Chief Executive Officer of ProMIS Neurosciences.
  • In a cell system, the misfolded form of RACK1 was detected by ProMIS antibodies selective for this RACK1 isoform.
  • These preclinical findings support misfolded RACK1 as a potential therapeutic target for TDP-43 proteinopathy in non-SOD1 and non-FUS ALS as well as FTLD-TDP.

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

Retrieved on: 
Tuesday, February 7, 2023
Amyotrophic lateral sclerosis, Barrow Neurological Institute, Target, Alpha-synuclein, Disease, Research, Diagnosis, Neurodegeneration, Pathology, The Michael J. Fox Foundation, NDD, MJFF, Frontotemporal lobar degeneration, Precision medicine, International Center, PET, FTLD, Patient, Drug discovery, ALS, Kansas City University, National Center for Research Resources, Senior, AC, TAR, Engineering, Pharmaceutical industry, Medical imaging, Biotechnology

Fox Foundation for Parkinson’s Research (MJFF) and Target ALS Foundation (Target ALS) supporting research programs to enable diagnosis of TDP-43 (TAR DNA-binding protein 43), recognized as an important target in multiple neurodegenerative diseases (NDDs) such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) and as a prominent co-pathology in Alzheimer’s and Parkinson’s diseases.

Key Points: 
  • Fox Foundation for Parkinson’s Research (MJFF) and Target ALS Foundation (Target ALS) supporting research programs to enable diagnosis of TDP-43 (TAR DNA-binding protein 43), recognized as an important target in multiple neurodegenerative diseases (NDDs) such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) and as a prominent co-pathology in Alzheimer’s and Parkinson’s diseases.
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “It is an honor to have the support of MJFF and Target ALS, two leading international organizations that recognize the pressing need for diagnostics to detect pathological TDP-43.
  • AC Immune and its collaborators recently demonstrated their expertise in developing cutting-edge PET imaging agents by providing the first images of alpha-synuclein.
  • The development of a TDP-43 specific biofluid-based diagnostic test has the potential to more rapidly enable confirmed early diagnosis.”
    The MJFF and Target ALS grants collectively provide more than USD 500,000 in additional non-dilutive capital to support the advancement of diagnostic programs targeting TDP-43.

Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta

Retrieved on: 
Monday, December 5, 2022
Ix, Food and Drug Administration Amendments Act of 2007, Sale, Registration statement, Toxicity, Form, FTLD, Register, Proxy statement, CBI, Prospectus, Amyotrophic lateral sclerosis, Patient, Muscle atrophy, Failure, Nature, ALS, VISTA, Neurodegeneration, Proxy, Therapy, Risk, Compte rendu, Holding company, Security (finance), Pharmaceutical industry, Janssen, Yuman–Cochimí languages, Shareholder, Kineta

BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX) announced today that its Board of Directors has declared a special dividend in connection with the previously announced asset sale to Janssen Pharmaceutica NV (“Janssen”) and merger with Kineta, Inc. (“Kineta”).

Key Points: 
  • The special dividend will be equal to the gross proceeds of the asset sale to Janssen, net of amounts used or retained for Yumanity’s outstanding obligations and minimum cash requirement associated with the closing of the merger with Kineta.
  • Payment of the special dividend is conditioned upon the closing of both the asset sale to Janssen and merger with Kineta, which remain subject to the approval of Yumanity’s stockholders and other closing conditions.
  • The special meeting of Yumanity’s stockholders to consider and vote upon the asset sale and merger is scheduled for December 13, 2022.
  • This press release may be deemed to be solicitation material with respect to the proposed transactions between Yumanity and Kineta and between Yumanity and Janssen.

Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
Monday, November 14, 2022
Sale, Registration statement, Amyotrophic lateral sclerosis, Failure, Neurodegeneration, ALS, Proxy, Food and Drug Administration Amendments Act of 2007, Form, Muscle atrophy, Toxicity, Prospectus, FTLD, Nature, Ix, Compte rendu, Register, Risk, Proxy statement, Security (finance), Yuman–Cochimí languages, Shareholder, Janssen, Kineta

This press release may be deemed to be solicitation material with respect to the proposed transactions between Yumanity and Kineta and between Yumanity and Janssen.

Key Points: 
  • This press release may be deemed to be solicitation material with respect to the proposed transactions between Yumanity and Kineta and between Yumanity and Janssen.
  • In connection with the proposed transactions, on August 29, 2022, Yumanity filed with the SEC a registration statement on Form S-4 (the Initial Registration Statement), as amended by Amendment No.
  • 2 to the Initial Registration Statement filed with the SEC on October 24, 2022 and Amendment No.
  • Yumanity subsequently filed the Proxy Statement on November 10, 2022, which is being mailed to stockholders of record as of the close of business on November 4, 2022.

Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.

Retrieved on: 
Thursday, November 10, 2022
Food and Drug Administration Amendments Act of 2007, Ix, Risk, Sale, Growth, Therapy, Janssen Pharmaceuticals, Company, Registration statement, Merck & Co., Ownership, Special, Prospectus, Securities Act of 1933, SEC, Compte rendu, Form, U.S. Securities and Exchange Commission, Cancer, Patient, Private Securities Litigation Reform Act, Phrase, Amyotrophic lateral sclerosis, Merck, Proxy statement, FTLD, Johnson & Johnson, Muscle atrophy, Toxicity, Register, PIPE, GLOBE, VISTA, Nature, CBI, Failure, Proxy, ALS, Neurodegeneration, Security (finance), Pharmaceutical industry, Property management, Holding company, Nasdaq, Janssen, Kineta, Shareholder, Yuman–Cochimí languages

Yumanity will mail the definitive proxy statement/prospectus (the Proxy Statement) to stockholders of record as of the close of business on November 4, 2022.

Key Points: 
  • Yumanity will mail the definitive proxy statement/prospectus (the Proxy Statement) to stockholders of record as of the close of business on November 4, 2022.
  • This press release may be deemed to be solicitation material with respect to the proposed transactions between Yumanity and Kineta and between Yumanity and Janssen.
  • In connection with the proposed transactions, on August 29, 2022, Yumanity filed with the U.S. Securities and Exchange Commission (the SEC) a registration statement on Form S-4 (the Initial Registration Statement), as amended by Amendment No.
  • 3 to the Initial Registration Statement filed with the SEC on November 4, 2022 (together with the Initial Registration Statement, the Registration Statement), which contains a preliminary proxy statement and prospectus.

Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta

Retrieved on: 
Monday, August 29, 2022
Amyotrophic lateral sclerosis, Phrase, Patient, FTLD, Prospectus, Securities Act of 1933, Ix, Register, Therapy, Toxicity, Sale, SEC, U.S. Securities and Exchange Commission, Registration statement, Muscle atrophy, GLOBE, Neurodegeneration, Form, Failure, VISTA, Risk, CBI, Private Securities Litigation Reform Act, ALS, Nature, Pharmaceutical industry, Online gambling, Security (finance), Yuman–Cochimí languages, Janssen, Shareholder, Nasdaq, Kineta

The Registration Statement contains a preliminary proxy statement and prospectus in connection with Yumanitys previously announced proposed asset sale to Janssen Pharmaceutica NV (Janssen) and merger with Kineta, Inc. (Kineta).

Key Points: 
  • The Registration Statement contains a preliminary proxy statement and prospectus in connection with Yumanitys previously announced proposed asset sale to Janssen Pharmaceutica NV (Janssen) and merger with Kineta, Inc. (Kineta).
  • Although the Registration Statement has not yet become effective and the information contained therein is subject to change, it provides important information about Yumanity and the proposed transactions.
  • This press release may be deemed to be solicitation material with respect to the proposed transactions between Yumanity and Kineta and between Yumanity and Janssen.
  • In connection with the proposed transactions, Yumanity filed with the SEC on August 29, 2022 the Registration Statement, which contains a preliminary proxy statement and prospectus.

Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, August 4, 2022
U.S. Securities and Exchange Commission, Compte rendu, Risk, Muscle atrophy, Phrase, Failure, Form, Private Securities Litigation Reform Act, SEC, Sale, Toxicity, Prospectus, Amyotrophic lateral sclerosis, FTLD, Company, Neurodegeneration, Nature, Securities Act of 1933, ALS, Ix, Yuman–Cochimí languages, Kineta, Shareholder, Janssen, Nasdaq

Yumanitys drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases.

Key Points: 
  • Yumanitys drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases.
  • This press release may be deemed to be solicitation material with respect to the proposed transactions between Yumanity and Kineta and between Yumanity and Janssen.
  • Yumanity will mail the proxy statement/prospectus to the Yumanity stockholders, and the securities may not be sold or exchanged until the registration statement becomes effective.
  • Investors and securityholders of Yumanity and Kineta are urged to read these materials when they become available because they will contain important information about Yumanity, Kineta and the proposed transactions.